【GReader】Hah, just kidding! - http://j.mp/eSGo26

Introducing the @ESGO_society 2026 Social Media Ambassador Team https://t.co/QhaGGHiCno #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ESGO #ESGO26 #ESGO2026

$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26

«@MillionDollar_2 «@ItsADifference R.I.P. To all the people we lost this year and lord please (cont) http://t.co/LSvcFDQr

Update from #ESGO26: Expert insights on the #PYNNACLE Phase 2 interim analysis from the ovarian cancer cohort Evaluating rezatapopt*, a first-in-class p53 reactivator, in #TP53 Y220C–mutant advanced solid tumours 📺 w/ Profs Domenica Lorusso and Jean-Sebastien Frenel Poster:

Insights from ESGO 2026 - Ahmed Y. Abdelbadee Hefnawy https://t.co/ed6VR3glCX #OncoDaily #Oncology #Cancer #Health #Medicine #ESGO26 #OvarianCancer #GynOnc #MedX #MedTwitter

“Engage Patient Advocacy Seminar”#ESGO26 @EngageEsgo @DarjaMolan @ESGO_society

Profs Domenica Lorusso & Jean-Sebastien Frenel share key insights from the PYNNACLE Phase 2 interim analysis at #ESGO26. Rezatapopt* shows promise in #TP53 Y220C–mutant ovarian cancer. Early patient ID & genomic profiling are key. 📺 Check out the video & poster:

Update from #ESGO26: #PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort Evaluating #rezatapopt*, a first-in-class p53 reactivator, in TP53 Y220C–mutant advanced solid tumours 📺 Video in this post 🔗 View/download the poster: https://t.co/ymOyWByzIM

At ESGO26 researchers tackled some of gynecologic oncology’s biggest questions: optimal surgery timing, chemotherapy scheduling, immunotherapy in platinum-resistant disease, and how molecular profiling can guide treatment decisions. Read more: https://t.co/A7ha9ZLpgF

At @esgo_society researchers shared pivotal data on surgery timing, chemotherapy scheduling, immunotherapy combinations, and real-world care patterns in advanced ovarian cancer. These findings are shaping future treatment strategies and improving outcomes https://t.co/qmj2yJ3FsT

Update from PYNNACLE Phase 2 at #ESGO26 Rezatapopt* = rapid, durable & broad antitumour activity in heavily pretreated patients with TP53 Y220C-mutated advanced #ovariancancer, where effective targeted therapies/biomarkers are limited How can we prioritise early+accurate

European Society of Gynaecological Oncology - Join the 27th ESGO 2026 in Copenhagen @ESGO_society https://t.co/jAPE5OrZDF #Cancer #CancerResearch #ESGO26 #Medicine #MedX #MedNews #MedEd #Health #GynaecologicalOncology #Oncology #OncoDaily

European Society of Gynaecological Oncology is Accepting Abstracts @ESGO_society https://t.co/5noInkUFbj #Cancer #ESGO25 #ESGO26 #Medicine #Health #MedX #MedNews #MedEd #Abstracts #GynOnc #Oncology #OncoDaily

📢 ESGO26: Key takeaways from Copenhagen The 27th European Congress on Gynaecological Oncology (ESGO26) highlighted cutting-edge insights across surgery, chemotherapy, immunotherapy, and molecular profiling. Read more: https://t.co/A7ha9ZLpgF #ESGO26

New research from @DanaFarber’s Panos Konstantinopoulos presented at #ESGO26 shows ACR-368, a potent, selective CHK1/2 inhibitor produced promising response rates in patients with BM+, platinum-resistant endometrial cancer. Strongest responses seen in patients w/serous EC.